Activity of trovafloxacin against antibiotic-resistant bacterial pathogens

Infectious Diseases in Clinical Practice

Volumn 8, Issue 4 SUPPL. 1, 1999, Pages

  Thomson, Kenneth S ^a   Moland, Ellen S ^a   Sanders, Christine C ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; IMIPENEM; NALIDIXIC ACID; OFLOXACIN; PIPERACILLIN; TAZOBACTAM; TROVAFLOXACIN; VANCOMYCIN;

ACINETOBACTER; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BURKHOLDERIA CEPACIA; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; GENE MUTATION; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS PNEUMONIAE;

EID: 0032930619     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019048-199905001-00003     Document Type: Article

References (31)

1. Everett MJ, Jin YF, Ricci V, et al. Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals. Antimicrob Agents Chemother 1996;40:2380-6.
2. Ng EY, Trucksis M, Hooper DC. Quinolone-resistant mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob Agents Chemother 1996;40:1881-8.
3. Pena C, Albareda JM, Pollares R, et al. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrob Agents Chemother 1995;39:520-4.
4. Sanders CC, Sanders WE Jr, Thomson KS. Fluoroquinolone resistance in staphylococci: new challenges. Fur J Clin Microbiol Infect Dis 1995;14(1 Suppl):6-11.
5. Thomson KS, Sanders WE Jr, Sanders CC. U.S.A. resistance patterns among UTI pathogens. J Antimicrob Chemother 1994;33(Suppl A):9-15.
6. Acar JF, Goldstein FW. Trends in bacterial resistance to fluoroquinolones. Clin Infect Dis 1997;24(1 Suppl): S67-S73.
7. Chow AW, Wong J, Bartlett KH, et al. Cross-resistance of Pseudomonas aeruginosa to ciprofloxacin, extended-spectrum β-lactams, and aminoglycosides and susceptibility to antibiotic combinations. Antimicrob Agents Chemother 1989;33:1368-72.
8. Deguchi T, Yasuda M, Nakano M, et al. Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae. J Antimicrob Chemother 1997;40:543-9.
9. Fung-Tomc J, Kolek B, Bonner DP. Ciprofloxacin-incluced, low-level resistance to structurally unrelated antibiotics in Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1993;37:1289-96.
10. Kaatz GW, Leo SM, Ruble CA. Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1993;37:1086-95.
11. Levy SB. Active efflux mechanisms for antimicrobial resistance. Antimicrob Agents Chemother 1992;36:695-703.
12. Sanders CC, Sanders WE Jr, Goering RV, et al. Selection of multiple antibiotic resistance by quinolones, β-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes. Antimicrob Agents Chemother 1984;26:797-801.
13. Schaberg DR, Dillon WI, Terpenning MS, et al. Increasing resistance of enterococci to ciprofloxacin. Antimicrob Agents Chemother 1992;36:2533-5.
14. Srikumar R, Kon T, Gotoh N, et al. Expression of Pseudomonas aeruginosa multidrug efflux pumps MexA-MexB-OprM and MexC-MexD-OprJ in a multidrug-sensitive Escherichia coli strain. Antimicrob Agents Chemother 1998;42:65-71.
15. Bauernfeind A. Comparison of the antibacterial activities of the quinolones BAY 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother 1997;40:639-51.
16. Cohen MA, Huband MD, Gage JW, Yoder SL, Roland GE, Gracheck SJ. In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin. J Antimicrob Chemother 1997;40:205-11.
17. Dembry LM, Farrel PA, Orcutt DR, Gerrity LA, Andriole VT. In-vitro activity of trovafloxacin against sensitive and resistant aerobic bacteria using the standard microdilution broth method and E test. J Antimicrob Chemother 1997;39(Suppl B):34-42.
18. Endtz HP, Mouton JW, denHollander JG, et al. Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections. Antimicrob Agents Chemother 1997;41:1146-9.
19. Felmingham D, Robbins MJ, Ingley K, et al. In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates. J Antimicrob Chemother 1997;39 (Suppl B):43-9.
20. Hoogkamp-Korstanje JAA. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin, and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections. J Antimicrob Chemother 1997;40:427-31.
21. Pascual A, Lopez-Hernandez I, Martinez-Martinez L, et al. In-vitro susceptibilities of multiresistant strains of Acinetobacter baumannii to eight quinolones [letter]. J Antimicrob Chemother 1997;40:140-2.
22. Rolston KVI, Ho DH, LeBlanc B, et al. In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer. J Antimicrob Chemother 1997;39 (Suppl B):15-22.
23. Thomson KS, Chartrand SA, Sanders CC, et al. Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae. Antimicrob Agents Chemother 1997;41:478-80.
24. Visalli MA, Bajaksouzian S, Jacobs MR, et al. Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfernentative rods. Antimicrob Agents Chemother 1997;41: 1475-81.
25. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A4. Villanova (PA): National Committee for Clinical Laboratory Standards; 1997.
26. Thomson KS, Sanders CC. Dissociated resistance among fluoroquinolones. Antimicrob Agents Chemother 1994; 38:2095-100.
27. Thomson KS, Sanders CC. The effects of increasing levels of quinolone resistance on in vitro activity of four quinolones. J Antimicrob Chemother 1998;42:179-37.
28. Thomson KS, Sanders CC, Hayden ME. In vitro studies with five quinolones: evidence for changes in relative potency as quinolone resistance rises. Antimicrob Agents Chemother 1991;35:2329-34.
29. Fournier B, Hooper DC. Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity. Antimicrob Agents Chemother 1998;42:121-8.
30. Schmitz F-J, Jones ME, Hofmann B, et al. Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC. Antimicrob Agents Chemother 1998;42:1249-52.
31. Takahashi H, Kikuchi T, Shoji S, et al. Characterization of gyrA, gyrB, grlA and grlB mutations in fluoroquino ones-resistant clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 1998;41:49-57.